Standout Papers
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma (2009)
- Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS) (2011)
Immediate Impact
19 from Science/Nature 184 standout
Citing Papers
Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
2022 Standout
Lung cancer
2021 Standout
Works of Emma Duffield being referenced
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
2011 Standout
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
2009 Standout
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Emma Duffield | 7088 | 5660 | 518 | 2029 | 21 | 8.3k | |
| José Rodrigues Pereira | 6929 | 6203 | 586 | 1967 | 25 | 8.6k | |
| Jin-Ji Yang | 6454 | 5061 | 343 | 1977 | 12 | 7.5k | |
| Claire Watkins | 7692 | 7390 | 649 | 2865 | 41 | 10.8k | |
| Patrapim Sunpaweravong | 6959 | 5638 | 567 | 2141 | 56 | 8.3k | |
| Busyamas Chewaskulyong | 5373 | 4259 | 296 | 1645 | 20 | 6.3k | |
| Baohui Han | 5402 | 4288 | 297 | 1676 | 10 | 6.4k | |
| Haiyi Jiang | 8090 | 6737 | 492 | 2342 | 52 | 9.7k | |
| B. Findlay | 4771 | 6924 | 882 | 1696 | 44 | 9.0k | |
| В. А. Горбунова | 5438 | 4426 | 937 | 2215 | 59 | 7.0k | |
| Daniel de Castro | 4431 | 5940 | 768 | 1690 | 26 | 7.6k |
All Works
Loading papers...